Kieny MP, Gautier C, Tomasetto C, Kuhn I, Hareuveni M, Clertant P, Lathe R. Vaccination against polyoma virus (PyV) tumors using vaccinia-PyV recombinants: a major tumor-specific transplantation antigen (TSTA) epitope resides within the C-terminal segment of middle-T protein.
Int J Cancer 1990;
45:185-9. [PMID:
1688831 DOI:
10.1002/ijc.2910450133]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We previously reported that inoculation of rats with live vaccinia virus (VV) recombinants VVpyMT, VVpyLT expressing either the middle-T (MT) or large-T (LT) proteins of polyomavirus (PyV) can elicit immunity to challenge with syngeneic PyV-tumor cells. We now report the results of cross-vaccination studies. VVpyMT was ineffective against cells expressing LT protein but prevented development of MT-expressing cells. Conversely, the VVpyLT was ineffective against MT-expressing cells. In the two experiments performed, tumor growth enhancement rather than retardation was observed in VVpyLT-vaccinated animals receiving PyV-LT (FRLTI) challenge tumor cells. To determine the location of the major TSTA within MT, a further VV recombinant (VVpyMT/Cfr) was constructed that expresses only the unique C-terminal segment of MT. VVpyMT-Cfr and VVpyMT were equally effective in eliciting tumor immunity, indicating the presence of a major TSTA epitope within the unique C-terminal region of MT.
Collapse